VSVidar Søyseth

Vidar Søyseth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vidar Søyseth has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exposure to Polycyclic Aromatic Hydrocarbons, but Not to Dust or Fluorides, in the Norwegian Aluminum Industry Is Associated With Accelerated Annual Decline in Lung Function

    by Vidar Søyseth, Paul K. Henneberger, Jonas Christoffer Lindstrøm, Mohammed Abbas Virji, Gunnar Einvik, Berit Bakke, Johny Kongerud

    Purpose: The association between development of chronic airflow limitation and exposures in the aluminum industry is unknown. In a prospective study with nearly 10 years of annual measurements of forced expiratory volume in 1 s (FEV1) and forced vital Capacity (FVC) and concurrent estimates of exposure to dust, total fluorides (TotF) and polycyclic aromatic hydrocarbons (PAH) we investigated the relationship between each of these exposures and annual decline in FEV1 (dFEV1) and FVC (dFVC). Methods: Estimates of exposure to dust, TotF, and PAH were obtained from random samples of 8‐h shifts using personal samplers at each of seven Norwegian aluminum plants. A total of 18,332 measurements were used to create a job‐exposure matrix. The total number of available spirometries was 20,712 in 3872 workers. Data were analyzed using linear mixed modeling with inverse probability weights for dropouts. Results: We found that dFEV1 and dFVC increased during follow‐up with linear and quadratic components that were modified by PAH exposure. These linear and quadratic components were estimated at 2.5 mL/year ( p = 0.019) and 4.2 mL/year 2 ( p < 0.001) for dFEV1, and −2.6 mL/year ( p = 0.076) and 5.9 mL/year 2 ( p < 0.001) for dFVC, respectively, per quartile increase in PAH exposure. Conclusion: We found a significant effect modification of the relationship between dFEV1 and dFVC, and follow‐up time by PAH exposure, indicating that PAH exposure accelerates the annual decline in FEV1 and FVC.

  • Open Access

    It is unlikely that oxygen supplementation in COPD patients with chronic respiratory failure reduce cardiac troponin level

    by Natalia Kononova, Gunnar Einvik, Nils Henrik Holmedahl, Tor-Arne Hagve, Torbjørn Omland, Vidar Søyseth

    Cardiac troponin T (cTnT) is a biomarker of myocardial injury frequently elevated in COPD patients, potentially because of hypoxemia. This non-randomised observational study investigates whether long-term oxygen treatment (LTOT) reduces the cTnT level. We compared cTnT between COPD patients who were candidates for LTOT (n = 20) with two reference groups. Patients from both reference groups were matched with the index group using propensity score.Reference groups consists of institutional pulmonary rehabilitation patients (short-term group) (n = 105 after matching n = 11) and outpatients at a pulmonary rehabilitation clinic (long-term group)(n = 62 after matching n = 10). Comparison was done within 24 h after LTOT initiation in first reference group and within 6 months after inclusion in the second group. The geometric mean of (standard deviation in parentheses) cTnT decreased from 17.8 (2.3) ng/L (between 8 and 9 a.m.) to 15.4 (2.5) ng/L between 1 and 2 p.m. in the LTOT group, and from 18.4 (4.8) ng/L to15.4 (2.5) ng/L in group (1) The corresponding long-term results were 17.0 (2.9) ng/L at inclusion (between 10 and 12 a.m.) to 18.4 (2.4) ng/L after 3 months in the LTOT-group, and from 14.0 (2.4) ng/L to 15.4 (2.5) ng/L after 6 months in group (2) None of the differences in cTnT during the follow-up between the LTOT-group and their matched references were significant. Initiation of LTOT was not associated with an early or sustained reduction in cTnT after treatment with oxygen supplementation.


  • Open Access

    Systemic inflammation induced by exacerbation of COPD or pneumonia in patients with COPD induces cardiac troponin elevation

    by Vidar Søyseth, Natalia Kononova, Anke Neukamm, Nils Henrik Holmedahl, Tor-Arne Hagve, Torbjorn Omland, Gunnar Einvik

    Background: Troponin is a biomarker of myocardial injury. In chronic obstructive pulmonary disease (COPD), troponin is an important determinant of mortality after acute exacerbation. Whether acute exacerbation of COPD (AECOPD) causes troponin elevation is not known. Here, we investigated whether troponin is increased in AECOPD compared to stable COPD.Methods: We included 320 patients with COPD in the stable state and 63 random individuals from Akershus University hospital’s catchment area. All participants were ≥40 years old (mean 65·1 years, SD 7·6) and 176 (46%) were females. The geometric mean of high-sensitivity cardiac troponin T (hs-cTnT) was 6·9 ng/L (geometric-SD 2·6). They were followed regarding hospital admission for the subsequent 5 years.Results: During the 5-year follow-up, we noted 474 hospitalisations: Totally, 150 and 80 admissions were due to AECOPD or pneumonia, respectively. The geometric mean ratio with geometric SE(GSE) between cTnT at admission and stable state in AECOPD and pneumonia was 1·27 (GSE=1.11, p=0·023) and 1·28 (GSE=1.14, p=0·054), respectively. After inclusion of blood leucocyte count and C reactive protein at hospitalisation, these ratios attenuated to zero. However, we estimated an indirect of AECOPD and pneumonia on the ratio between hs-cTnT at admission and the stable state to 1·16 (p=0·022) and 1·22 (p=0·008), representing 91% (95% CI 82% to 100%) and 95% (95% CI 83% to 100%) of the total effects, respectively.Conclusion: AECOPD and pneumonia in patients with COPD is associated with higher cTnT levels. This association appears to be mediated by systemic inflammation.


  • Cardiac troponin increases in COPD patients hospitalised for pneumonias as well as exacerbations

    by Vidar Søyseth, Natalia Kononova, Gunnar Einvik

    We included 383 stable COPD patients in a follow-up study of subsequent hospitalisations. The objective of the study was to investigate the changes in high sensitive cardiac troponin T (hs-cTnT) from baseline to hospital admission. At inclusion 25 patients had respiratory failure (group 1) and participated in a study of long-term oxygen treatment. Group 2 consisted of 63 COPD controls without respiratory failure, 175 patients were candidates to an RCT with statins, and the remaining 118 patients were recruited as controls to a study of hospitalised for acute exacerbation of COPD (AECOPD). The mean age was 65 years (SD: 7.5) and 203 (53 %) were females. The geometric mean of hs-cTnT at baseline was 7.2 ng/litres (GSD: 2.6). At baseline hs-cTnT was positively associated with age (p < 0.001) and history of arterial hypertension (p = 0.018), whereas hs-cTnT was negatively associated with FEV1 (p < 0.001). Finally, hs-cTnT was lower in female than males (p < 0.001). During 3 years follow-up, there were 335 hospitalisations in 134 patients (40 %). The four most frequent diagnoses were benign respiratory diseases (201, 60 %), cardiovascular diseases (34, 10 %), gastro-intestinal diseases (19, 5.7 %) and cancer (11, 3.3 %). After adjustment for age, gender, creatinine, FEV1, and arterial hypertension linear mixed model showed that the ratio between hs-cTnT at admission and baseline was 1.40 (p<0.001) for AECOPD, 1.42 (p<0.001) for pneumonia, and 2.01 (p<0.001) for cardiovascular diseases. Conclusion: In stable COPD patients, hs-cTnT increased with 40 % at hospital admission for AECOPD as well as pneumonia.


  • Open Access

    Annual decline in forced expiratory volume and airway inflammatory cells and mediators in a general population-based sample

    by Natalia Kononova, Liv Ingunn Bjoner Sikkeland, Faiza Mahmood, Maria Vistnes, Johny Kongerud, Gunnar Einvik, Vidar Søyseth

    Few studies have examined the relationships between sputum inflammatory markers and subsequent annual decline in forced expiratory volume in 1 s (dFEV1). This study investigated whether indices of airway inflammation are predictors of dFEV1 in a general population-based sample. The study, conducted from 2003 to 2005, included 120 healthy Norwegian subjects aged 40 to 70 years old. At baseline, the participants completed a self-administered respiratory questionnaire and underwent a clinical examination that included spirometry, venous blood sampling, and induced sputum examination. From 2015 to 2016, 62 (52%) participants agreed to a follow-up examination that did not include induced sputum examination. Those with a FEV1/forced vital capacity (FVC) ratio < 0.70 underwent a bronchial reversibility test. The levels of cytokines, pro-inflammatory M1 macrophage phenotypes were measured in induced sputum using bead-based multiplex analysis. The associations between cytokine levels and dFEV1 were then analysed. The mean dFEV1 was 32.9 ml/year (standard deviation 26.3). We found no associations between dFEV1 and the baseline indices of sputum inflammation. Seven participants had irreversible airflow limitation at follow-up. They had lower FEV1 and gas diffusion at baseline compared with the remaining subjects. Moreover, two of these individuals had a positive reversibility test and sputum eosinophilia at baseline. In this cohort of presumably healthy subjects, we found no associations between sputum inflammatory cells or mediators and dFEV1 during 10 years of follow-up.


  • Open Access

    Var kols forklaringen?

    by Vidar Søyseth

    Kommentar - Troponin finnes i tre isoformer – C, I og T.


  • Open Access

    The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients

    by Anke Neukamm, Gunnar Einvik, Arne Didrik Høiseth, Vidar Søyseth, Nils Henrik Holmedahl, Natalia Kononova, Torbjørn Omland

    Cardiovascular disease (CVD) is a common comorbidity in chronic obstructive pulmonary disease (COPD). Cardiac troponin (cTn) elevation, indicating myocardial injury, is frequent during acute COPD exacerbations and associated with increased mortality. The prognostic value of circulating cTnT among COPD patients in the stable state of the disease is still unknown. The purpose of the present study was to assess the association between circulating cTnT measured by a high sensitive assay (hs-cTnT) and all-cause mortality among patients with stable COPD without overt CVD. In a prospective cohort study we included 275 patients from the Akershus University Hospital’s outpatient clinic and from Glittre, a pulmonary rehabilitation clinic. COPD-severity and cardiovascular risk factors were assessed, and time to all-cause death was recorded during a mean follow-up time of 2.8 years. One hundred-eighty patients (65%) had hs-cTnT concentrations ≥ the level of detection (5.0 ng/L) and 66 patients (24%) had hs-cTnT above the normal range (≥14.0 ng/L). In total, 47 patients (17%) died. hs-cTnT concentrations in the ranges <5.0, 5.0–13.9 and ≥14 ng/L were associated with crude mortality rates of 2.8, 4.4 and 11.0 per 100 patient-years, respectively. In adjusted analyses the hazard ratios (95% confidence intervals) for death were 1.7 (0.8–3.9) and 2.9 (1.2–7.2) among patients with hs-cTnT concentrations 5.0–13.9 and ≥14 ng/L, respectively, compared to patients with hs-cTnT <5.0 ng/L. hs-cTnT elevation is frequently present in patients with stable COPD without overt CVD, and associated with increased mortality, independently of COPD-severity and other cardiovascular risk factors.


  • The influence by body mass index on annual lung function decline is not related to smoking status

    by Gunnar Einvik, Johnny Kongerud, Berit Bakke, Vidar Søyseth

    Background: Smoke cessation is associated with a decrease in lung function decline compared to sustained smoking, yet it is also associated with weight gain. We hypothesized that increased body mass index (BMI) suppresses the beneficial effects by smoke cessation on lung function. Methods: In a longitudinal cohort of Norwegian aluminum industry workers, spirometry, BMI and smoking status were available in 4142 persons (mean age 29, 85% male). The influence by BMI changes on forced vital capacity (FVC), forced expiratory volume during 1st second (FEV1) and FEV1/FVC in relation to smoking cessation were assessed in linear mixed model analyses, adjusted for baseline age and gender. Results: The unadjusted annual increase (standard error) in BMI was 0.16 (0.01), 0.12 (0.01) and 0.12 (0.01) in never-smokers, quitters and sustained smokers, respectively. In the adjusted analyses , an increase in BMI was independently associated with higher annual decline in FEV1 and FVC in all groups. Furthermore, an increase in BMI was associated with an increase in FEV1/FVC, independent of smoking status. | | FEV1 (ml) | FVC (ml) | FEV1 /FVC (%) | || | Never-smokers (N=6128) | -3.0 (2.4)* | -6.1 (0.6)* | 0.32 (0.01)* | | Quitting smokers (N=2547) | -1.9 (0.7)* | -5.1 (0.9)* | 0.04 (0.01)* | | Persistent smokers (N=11079) | -1.6 (0.4)* | -4.2 (0.4)* | 0.03 (0.01)* | * *p<0.001 Multivariate adjusted annual change (standard error) in FEV1, FVC and FEV1/FVC per unit increase in BMI, stratified by smoking status Conclusion: Weight-gainers among smoke quitters have higher annual lung function decline, with a pattern towards restriction, but this effect was not different in never-smokers or sustained smokers.

  • Open Access

    Annual decline in forced expiratory volume is steeper in aluminum potroom workers than in workers without exposure to potroom fumes

    by Vidar Søyseth, Paul K. Henneberger, Gunnar Einvik, Mohammed Abbas Virji, Berit Bakke, Johny Kongerud

    Background: Aluminum potroom exposure is associated with increased mortality of COPD but the association between potroom exposure and annual decline in lung function is unknown. We have measured lung volumes annually using spirometry from 1986 to 1996. The objective was to compare annual decline in forced expiratory volume in 1 s (dFEV1) and forced vital capacity (dFVC).Methods: The number of aluminum potroom workers was 4,546 (81% males) and the number of workers in the reference group was 651 (76% males). The number of spirometries in the index group and the references were 24,060 and 2,243, respectively.Results: After adjustment for confounders, the difference in dFEV1 and dFVC between the index and reference groups were 13.5 (P < 0.001) and −8.0 (P = 0.060) ml/year.Conclusion: Aluminum potroom operators have increased annual decline in FEV1 relative to a comparable group with non‐exposure to potroom fumes and gases. Am. J. Ind. Med. 59:322–329, 2016. © 2016 The Authors. American Journal of Industrial Medicine Published by Wiley Periodicals, Inc.


  • The influence of heart failure co-morbidity on high-sensitivity troponin T levels in COPD exacerbation in a prospective cohort study: data from the Akershus cardiac examination (ACE) 2 study

    by Arne Didrik Høiseth, Jon Brynildsen, Tor-Arne Hagve, Geir Christensen, Vidar Søyseth, Omland Torbjørn, Helge Røsjø

    Context: Troponin (hs-TnT) levels predict mortality after acute exacerbation of COPD (AECOPD). Whether this is independent of heart failure (HF) is not established. Material and methods: Prospectively included AECOPD patients adjudicated for acute HF categorized into three groups: (A) AECOPD, but acute HF the primary cause for hospitalization; (B) AECOPD the primary cause, but co-existing myocardial dysfunction and (C) AECOPD without myocardial dysfunction. Results: About 103 AECOPD patients; 18% A, 27% B and 54% C. Hs-TnT level differed between the groups: (ng/l, median) A: 41, B: 25 and C: 15, p = 0.03 for A versus B and p = 0.005 for B versus C. During a median 826 days, 47% died. In Cox analysis, hs-TnT levels remained associated with mortality (hazard ratio per 10 ng/l 1.3, p < 0.0001). Conclusion: hs-TnT levels are influenced by myocardial dysfunction/HF in AECOPD, but provide independent prognostic information. The prognostic merit of hs-TnT cannot be attributed to HF alone.